Fosun Antigen Submits Hong Kong IPO Application Following Pharma Spinoff Approval on June 26

Fosun Pharma and Fosun International received approval from Hong Kong Exchanges and Clearing to spin off Fosun Antigen and list it on the Main Board today (June 26). Fosun Antigen has submitted its IPO application for H-share listing on the Hong Kong Stock Exchange. Following the spinoff completion, Fosun Antigen will remain a subsidiary of Fosun Pharma.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments